Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS1191-0445 gene therapy in hemophilia A
NCT06833983Phase 3Recruiting
- Sponsor
- Gritgen Therapeutics Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Nov 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
A Phase 3 trial of GS001 in hemophilia A, sponsored by Gritgen Therapeutics Co., Ltd.. Started Mar 2025; status: recruiting.
02
Drugs
GS001
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT06833983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06833983.